Group items matching

in title, tags, annotations or url

This announcement solicits applications for two (2) separate competitions, HRSA-17-013 Autism Field-Initiated Innovative Research Studies and HRSA-17-014 Autism Longitudinal Data Project.  The purpose of the Autism Field-Initiated Innovative Research Studies and the Autism Longitudinal Data Project competitions are to support the conduct of empirical research that advances the evidence base on interventions to improve the health and wellbeing of children and adolescents with Autism spectrum disorders (ASD), with a special focus on addressing the needs of underserved populations.  These competitions will address the critical need that exists for research on the barriers to screening, diagnosis, and receipt of evidence-based interventions.

Autism Speaks invites applications from predoctoral students interested in pursuing careers in  Autism research. The Dennis Weatherstone Fellows will work directly with mentors who are leading scientists in Autism related research. This program supports the growth of a promising cadre of young  scientists who will make Autism research their chosen field. In order to cross-fertilize ideas and facilitate a network of collaboration, the Weatherstone program will include group interaction among the class of fellows and an annual meeting with the Weatherstone family and the Stavros Niarchos Foundation. More information about the Weatherstone program is available on the Autism Speaks website.

Autism Speaks places a high priority on innovation and has designed the Trailblazer Award to respond quickly to fund highly novel transformative projects. The Trailblazer Award mechanism supports highly novel "out of the box" Autism-relevant research that open  new avenues to understanding the causes, diagnosis, subtyping, prevention, treatments, and cure of Autism spectrum disorders. The Trailblazer Award mechanism is designed to fund small  investigator-initiated high risk/high impact projects that are potentially transformative, paradigm shifting, and/or will overcome significant roadblocks in Autism research within a 12 month period. 

The Autism Science Foundation is inviting applications for its Pre- and Postdoctoral Training Awards and Medical School Gap Year Research Training Awards from graduate students, medical students, and postdoctoral fellows interested in pursuing careers in basic and clinical research relevant to Autism spectrum disorders. The proposed training must be scientifically linked to Autism and may be broadened to include training in a closely related area of scientific research, including but not limited to human behavior across the lifespan (language, learning, behavior, communication, social function, motor skills and planning, epilepsy, sleep, repetitive disorders); neurobiology (anatomy, development, neuroimaging); pharmacology; neuropathology; genetics; epigenetics; genomics; epigenomics; immunology; molecular and cellular mechanisms; studies employing model organisms and systems; and studies of treatment and service delivery.

The BTI program welcomes LOIs that span the breadth of science that SFARI normally supports, including genetics, molecular mechanisms, circuits and systems, and clinical science. While the organization encourages applications from scientists who are working on autism-related projects, the program is also open to researchers who are not currently working on autism but who are interested in starting research projects in autism and who have expertise that could be brought to bear on the disorder.

This award program is designed to enhance our existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. We will consider proposals at all of these levels. The maximum budget is $60,000, including indirect costs for one (1) year, non-renewable. Explorer Awards are intended to provide resources to support exploratory experiments that will strengthen hypotheses and lead to the formulation of competitive applications for subsequent larger-scale funding by SFARI or other organizations. Innovative, high-risk/high-impact proposals are encouraged. We especially encourage applications from investigators who are new to the field of autism, but who have expertise that could be brought to bear on this complex disorder.

The Simons Foundation Autism Research Initiative improves the understanding, diagnosis, and treatment of Autism spectrum disorders by funding innovative research of the highest quality and relevance. To that end, SFARI is inviting applications for its SFARI Research Awards from individuals ready to conduct bold and rigorous research. The goal of the award is to provide support for investigation of key unresolved research questions in Autism, particularly those that connect genetic etiologies to brain function and behavior. The program welcomes risk and novelty, but they are not required criteria for a proposal to be considered meritorious.

The mission of the Simons Foundation Autism Research Initiative  is to improve the diagnosis and treatment of Autism spectrum disorders through the funding, catalyzing, and driving of high-quality research. To that end, the program is seeking applications for SFARI awards from individuals eager to conduct bold, imaginative, rigorous, and relevant research.

The mission of the Simons Foundation Autism Research Initiative (SFARI) is to improve the diagnosis and treatment of Autism spectrum disorders by funding innovative research of the highest quality and relevance throughout the world. To this end, we solicit applications for SFARI Awards from individuals who will conduct bold, imaginative, rigorous and relevant research.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that would develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R21 grant mechanism, while RFA- MH-19-120 uses the R01 grant mechanism. Applications with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may be more appropriate for the R01 mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be more appropriate for this FOA (R21 mechanism).

Through the program, grants of up to $100,000 over eighteen months will be awarded to projects that advance our understanding of the genetic basis of autism spectrum disorder. Data to be analyzed through the program will include whole-exome and genome-wide genotyping data from approximately forty-five hundred individuals with ASD enrolled in SPARK and their biological parents. Approximately half of these families will also have genomic data from an unaffected sibling. Whole-genome sequencing data from an additional four hundred ASD individuals, plus their biological parents and unaffected siblings, is also expected to be available. In addition, a limited phenotypic data set on all participants will be available.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). 

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R01 grant mechanism, while RFA-MH-19-121 uses the R21 grant mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for the R21 mechanism. Applicants with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may wish to use this FOA (R01 mechanism).

SFARI is seeking to add additional clinical sites to its existing network for the purposes of recruiting SPARK participants. Selected sites will receive funding on an annual basis for up to three years, subject to periodic performance review. Support for a clinical site will include the following allowable costs: principal investigator salary - up to 10 percent effort for a PI or PI(s); site coordinator(s) salary - up to two full-time coordinators or the equivalent; funds for conducting community outreach in catchment area (excludes direct payment to participants); funds for recruitment and retention materials and supplies such as tablets to assist families with online registration; and, if applicable, funds to support return of genetic and behavioral results.

We seek applications from independent investigators who can devote a substantial portion of time to this effort. While we will not require a minimum Principal Investigator (PI) effort, we expect the PI to commit to a level of effort that reflects a leading role in the project. We encourage applications from researchers who are not currently working on autism, but who have expertise that could be brought to bear on this complex disorder. We will also accept collaborative grants involving multiple investigators.

We seek applications from independent investigators who can devote a substantial portion of time to this effort. While we will not require a minimum Principal Investigator (PI) effort, we expect the PI to commit to a level of effort that reflects a leading role in the project. We encourage applications from researchers who are not currently working on autism, but who have expertise that could be brought to bear on this complex disorder. We will also accept collaborative grants involving multiple investigators.

The Fiscal Year 2015 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP): Alcohol and Substance Abuse Research Program - $4.0 million Amyotrophic Lateral Sclerosis Research Program - $7.5 million Autism Research Program - $6.0 million Bone Marrow Failure Research Program - $3.2 million Breast Cancer Research Program - $120.0 million Duchenne Muscular Dystrophy Research Program - $3.2 million Epilepsy Research Program - $7.5 million Gulf War Illness Research Program - $20.0 million Joint Warfighter Medical Research Program - $50.0 million Lung Cancer Research Program - $10.5 million Military Burn Research Program - $8.0 million Multiple Sclerosis Research Program - $5.0 million Neurofibromatosis Research Program - $15.0 million Neurotoxin Exposure Treatment Parkinson's Research Program - $16.0 million Orthotics and Prosthetics Outcomes - $10.0 million Ovarian Cancer Research Program - $20.0 million Peer Reviewed Alzheimer's Research Program - $12.0 million Peer Reviewed Cancer Research Program - $50.0 million Peer Reviewed Medical Research Program - $247.5 million Peer Reviewed Orthopaedic Research Program - $30.0 million Prostate Cancer Research Program - $80.0 million Spinal Cord Injury Research Program - $30.0 million Tuberous Sclerosis Complex Research Program - $6.0 million Vision Research Program - $10.0 million

The purpose of this Funding Opportunity Announcement (FOA) is to support research to develop and pilot test strategies to assist transition-age youth with autism spectrum disorder (ASD) and their families or caretakers in planning for and smoothly transitioning into adult functioning and adult services.The ultimate goal is to develop models for transition to adult supports and services that effectively prevent lapses in services and supports; enhance functioning in community settings such as educational, social, familial, and other settings; maintain or improve health, safety, and quality of life; and reduce or maintain reductions in ASD-related symptoms.

The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. It is expected that the proposed clinical trial begin no later than 12 months after the award date, or 18 months after the award date for U.S. Food and Drug Administration (FDA)-regulated studies.

The ARP Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with ASD. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.